Evidence map›Paper›PMID 40727491›Full record

ArticleIn silico pharmacology2025

The inhibitory effects of

Cecilia Oluwamodupe, Olorunfemi Oyewole Babalola, Paul Olamide Ottu, Erinayo Tolulope Aladeteloye, Elizabeth Temilolaoluwa Mogaji, Elijah Olamide Olumodeji, Victor Richard Adekanle, Olusola Olalekan Elekofehinti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cecilia OluwamodupePharmaceutical Biochemistry Research Lab., Department of Biochemistry, Olusegun Agagu University of Science and Technology Okitipupa, Okitipupa, Ondo State Nigeria.
Olorunfemi Oyewole BabalolaTeady Bioscience Research Laboratory, Ilaramokin, Ondo State Nigeria.
Paul Olamide OttuTeady Bioscience Research Laboratory, Ilaramokin, Ondo State Nigeria.
Erinayo Tolulope AladeteloyePharmaceutical Biochemistry Research Lab., Department of Biochemistry, Olusegun Agagu University of Science and Technology Okitipupa, Okitipupa, Ondo State Nigeria.
Elizabeth Temilolaoluwa MogajiPharmaceutical Biochemistry Research Lab., Department of Biochemistry, Olusegun Agagu University of Science and Technology Okitipupa, Okitipupa, Ondo State Nigeria.
Elijah Olamide OlumodejiPharmaceutical Biochemistry Research Lab., Department of Biochemistry, Olusegun Agagu University of Science and Technology Okitipupa, Okitipupa, Ondo State Nigeria.
Victor Richard AdekanlePharmaceutical Biochemistry Research Lab., Department of Biochemistry, Olusegun Agagu University of Science and Technology Okitipupa, Okitipupa, Ondo State Nigeria.
Olusola Olalekan ElekofehintiTeady Bioscience Research Laboratory, Ilaramokin, Ondo State Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid cell leukemia 1 (MCL-1), a crucial anti-apoptotic member of the B-cell lymphoma 2 (BCL-2) family, has been extensively documented to be overexpressed in a variety of cancers, where it is essential for fostering cancer cell survival and treatment resistance. Elevated levels of MCL-1 have been observed in hematological cancers, such as acute myeloid leukemia and multiple myeloma, as well as in multiple solid tumors. We therefore examined the potential inhibitory effects of

Indexed as

CancerCentella asiaticaHit compoundsMolecular docking analysisMyeloid cell leukemia-1

Identifiers

PMID40727491
PMCPMC12297120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.